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Abstract
In rare cases (1-8%) diabetic patients with end-stage renal disease (ESRD) suffer from diabetic nephropathy (dNP)
due to pancreatic diabetes mellitus (PDM). Aim of this study was to investigate differences in the outcome of
patients with PDM and those with type 2 diabetes.
In a retrospective study we evaluated 96 diabetic patients, who started hemodialysis (HD) in our dialysis centre
(1997-2005). In 12 patients PMD was diagnosed, and 84 patients had type 2 diabetes. In both groups we compared
vascular risk factors and prevalence of vascular diseases at the start of dialysis. We also evaluated incidence of
malnutrition, and 5-year survival in both patient groups.
The vascular risk factors were similar in both patient groups, also the prevalence of vascular diseases at the
initiation of HD was similar in both groups. In the patients with PDM the mean BMI (kg/m
2) was lower (22 + 3
versus 25 + 3), and also their serum albumin was lower (2.7 + 0.3 versus 3.4 + 0.3 g/dl, p < 0.05). Four of these
patients (33%) developed malnutrition (BMI < 18.5). In the patients with PDM the age adjusted 5-year survival was
significantly lower (8% versus 27%, p < 0.05) than in the type 2 diabetic patients.
Conclusions in HD-treated patients with type 2 diabetes or PDM the prevalence of vascular diseases was not
significantly different. The lower survival of PDM patients can be related to poor nutrition status.
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Introduction
In rare cases (1-8%) patients w/ith pancreatic diabetes
(PDM) develop diabetic nephropathy (dNP) with
ESRD [1-4] The aim of this retrospective study was to
investigate differences in the clinical outcome of ure-
mic patients with dNP due to type 2 diabetes or
PDM. There are only few data in the literature dealing
with PDM and ESRD [3]. In a recent study was
reported, that only 1-5% of diabetic patients with
ESRD suffer from pancreatic diabetes [Choudhuri et
al. 2009]. Aim of our study was to investigate preva-
lence of atherosclerosis and to evaluate differences in
the outcome of patients with PDM and those with
type 2 diabetes.
Patients
During the years 1997-2005 we selected 144 type 2 dia-
betic patients who started chronic hemodialysis (HD) in
our dialysis centre. We excluded patients with death
within the first three months of HD (n = 24), kidney
transplantation (n = 8) and patients (n = 16) with vascu-
lar nephropathy (vNP). Finally, a total of 96 patients
with dNP were included in a retrospective study, 12
patients of them with dNP due to PDM versus 84
patients with dNP caused by type 2 diabetes. The diag-
nosis of PDM was based on hyperglycemia after recur-
rent onset of acute pancreatitis and/or pancreas
resection. The diagnosis of dNP was based on protei-
nuria, normal urine sediment, normal kidney size and
long acting diabetes. The diagnosis of vNP was defined
as renal atherosclerosis and/or shrinkage of a kidney.
In both groups we compared major vascular risk fac-
tors and prevalence of vascular diseases at the start of
dialysis. We also evaluated incidence of malnutrition,
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prevalence of vascular diseases at the start of HD. Diag-
nosis of cerebrovascular disease (CVD), coronary artery
disease (CAD) and of peripheral vascular disease (PVD)
was described in the literature [5]. We also investigated
the nutritional status, the frequency of malnutrition and
of exocrine pancreatic insufficiency, associated with
chronic diarrhoea [6]. The observation period of the
study was five years. Thus, in our analysis, the endpoint
of the study was death by any cause, while the basal dis-
ease PDM or type 2 diabetes were considered as
covariables.
For statistical analysis the SPSS for Windows statisti-
cal program was used. The statistical methods included
the chi-squared test for comparing differences between
the groups, and the unpaired student’st e s tf o rt e s t i n g
unequal variances as well as the Kuscal test for compari-
sons among the groups. A p-value of less than 0.05 was
considered significant.
Results
At the time of initiating HD treatment the patients with
PDM were significantly younger than those with type 2
diabetes (mean age 56 versus 63 years). The vascular
risk factors were similar in both groups, only cholesterol
was lower in the PDM patients; the HbA1c values were
not different (mean control levels 7.5 versus 7.6%), how-
ever, the patients with PDM required significantly less
insulin. All baseline data of both patient groups are pre-
sented in Table 1. In our patients it can be assumed,
that dNP was the cause of ESRD. The clinical diagnosis
of dNP was confirmed by histological investigations in
44 diabetic patients.
The prevalence of macrovascular diseases at the start
of dialysis was not significantly different. The prevalence
of CAD was 66% in the type 2 diabetic patients versus
50% in the group. with PDM. The prevalence of CVD
was 33 versus 45% and PVD 50 versus 45%.
The nutritional status at the start of HD was poor in
the PDM patients. The frequency of underweight (BMI
< 21) was 50% versus 9% (p < 0.05). Four patients with
PDM (33%) developed malnutrition (BMI < 18.5). In six
patients an exocrine pancreatic insufficiency could be
observed (50%). The prognostic parameter s-albumin
was significantly lower in the PDM group (2.7 + 0.3 ver-
sus 3.4 + 0.3 g/l, p < 0.05). The 5- year survival was sig-
nificantly lower in the group with PDM 8% versus 27%
(p < 0.05) The observation period of the study was five
years. We measured the 5-year - absolute survival rates,
which describe the percentage of patients that are alive
five years after their disease is diagnosed. The most
common causes of death were cardiovascular events, in
the PDM group 60% versus 65% in the type 2 diabetic
patients. Infection was cause of death in 27% of the
PDM patients and 21% of the patients with type 2 dia-
betes (NS).
Discussion
Diabetes caused by exocrine pancreatic disease appears
to be underestimated and ma yc o m p r i s e8 %o rm o r eo f
the general diabetic patient population [4] In our study
the causes of PDM were chronic fibrocalculous pancrea-
titis (n = 8) and pancreas resection due to pancreas neo-
plasma (n = 4) The vascular risk factors were similar in
both patient groups. The traditional risk factors and the
non-traditional risk factors [7] are shown in Table 2.
Parathormon (PTH) was no routine measurement in
earlier years. PTH values were available in 68% of all
patients. ESRD patients with PDM versus type 2 dia-
betes show a similar vascular risk profile and a compar-
able high prevalence of vascular diseases, though
patients with PDM were younger. The CRP values, con-
sidered as vascular risk factors, were slightly higher in
the patients with PDM, but difference was not signifi-
cant. Similar data are described in the literature [8]. All
prognostic parameters are also summarized in Table 2.
It can be assumed that the low patient survival is asso-
ciated with the poor nutrition status of the PDM
patients. This study has several limitations particularly
Table 1 Baseline data at the start of dialysis
Pancreatic
diabetes
Type 2
diabetes
(n = 12) (n = 84)
Age (years) 56 ± 6* 63 ± 8*
Sex (female %) 50% 52%
Diabetes duration (years) 17 ± 7 18 ± 6
HbA1c (%) 7.5 ± 1.3 7.6 ± 1.1
Body weight (kg) 59 ± 7** 70 ± 11**
BMI (kg/m
2) 22 ± 3* 25 ± 4*
C-peptide basal (ng/ml) 0.9 ± 0.3* 1.9 ± 0.6*
Systolic blood pressure (mm Hg) 136 ± 12 137 ± 10
Diastolic blood pressure (mm
Hg)
86 ± 9 87 ± 8
Antidiabetic therapy (%)
Diet and sulfonylurea 0 5%
Conventional insulin therapy 50% 44%
Intensified insulin therapy 50% 41%
Insulin dose (IU/day) 22+11* 32+11*
Vascular access (n/%)
Arteriovenous fistula 10 (83%) 64 (76%)
Permcath-dialysis catheter 2 (17/%) 20 (24%)
Insulin dose (IU/day) 22 ± 11* 32 ± 16*
Duration of dialysis (hours//
week)
13 (12-15) 13 (12-15)
Kt/V (three month after start of
HD)
1.3 1.4
p < 0.05, **p < 0.01. Data are expressed as x+SD, x (range) or %
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on PTH-levels and residual renal function, and the
absence of more accurate methods of nutritional asses-
ment However, our results suggest that malnutrition is
possible explanation to the outcome differences.
Conclusion
The prevalence of atherosclerosis is not significantly dif-
ferent in both, patients on hemodialysis with PDM ver-
sus type2 diabetes. In patients with PDM the 5-year
surviv l is lower than in the type 2 diabetic patients. We
confirm, that there are limitations of our study, due to
the retrospective analysis of the data and due to the
small patient group with PDM.
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Table 2 Traditional and non-traditional risk factors and
prescribed medication
Pancreatic
diabetes
Type 2
diabetes
Traditional vascular risk factors
Fasting blood glucose (mg/dl) 146 ± 22 14 ± 22
Systolic blood pressure (mm Hg) 134 ± 12 136 ± 12
Diastolic blood pressure (mm Hg) 82 ± 7 84 ± 8
Uncontrolled hypertension 83% 90%
Cholesterol (mg/dl) 142 ± 42** 196 ± 36**
Smoking 33 30
Non-traditional risk factors
BMI < 21 (kg/m
2) 50% 9%
BMI < 18.5 (malnutrition) 3 3% 0
CRP (ng/ml) 1.4 ± 0.9 0.8 ± 0.6
Serum albumin (g/dl) 2.7 ± 0.3* 3.4+0.3*
Hemoglobin (gm/dl) 10 (8-12) 11 (8-13)
Triglycerides (mg/dl) 123 ± 44 156 ± 42
Fluid overload (ultrafiltration
necessary)
33% 24%
Prescribed medication
Iron substitution 27% 17%
25-hydroxy vitamin D 66% 43%
Statin 33% 44%
Aspirin 33% 29%
ACE inhibitors 50% 52%
*p < 0.05, **p < 0.01 Data are expressed as x+SD, x (range) or %
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